EX-4.2





 Exhibit 4.2 

Execution Version 
  

 
 VIRACYTE, INC. 

AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 
  












 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	1.	 	 Definitions
	  	 	1	 
			
	2.	 	 Registration Rights
	  	 	4	 
				
		 	2.1	  	Demand Registration	  	 	4	 
		 	2.2	  	Company Registration	  	 	6	 
		 	2.3	  	Underwriting Requirements	  	 	6	 
		 	2.4	  	Obligations of the Company	  	 	7	 
		 	2.5	  	Furnish Information	  	 	9	 
		 	2.6	  	Expenses of Registration	  	 	9	 
		 	2.7	  	Delay of Registration	  	 	9	 
		 	2.8	  	Indemnification	  	 	9	 
		 	2.9	  	Reports Under Exchange Act	  	 	11	 
		 	2.10	  	Limitations on Subsequent Registration Rights	  	 	11	 
		 	2.11	  	“Market Stand-off” Agreement	  	 	11	 
		 	2.12	  	Restrictions on Transfer	  	 	12	 
		 	2.13	  	Termination of Registration Rights	  	 	13	 
			
	3.	 	 Information and Observer Rights
	  	 	14	 
				
		 	3.1	  	Delivery of Financial Statements	  	 	14	 
		 	3.2	  	Inspection	  	 	15	 
		 	3.3	  	Observer Rights	  	 	15	 
		 	3.4	  	Termination of Information and Observer Rights	  	 	16	 
		 	3.5	  	Confidentiality	  	 	16	 
			
	4.	 	 Rights to Future Stock Issuances
	  	 	16	 
				
		 	4.1	  	Right of First Offer	  	 	16	 
		 	4.2	  	Termination	  	 	17	 
			
	5.	 	 Additional Covenants
	  	 	18	 
				
		 	5.1	  	Insurance	  	 	18	 
		 	5.2	  	Employee Agreements	  	 	18	 
		 	5.3	  	Employee Stock	  	 	18	 
		 	5.4	  	Board Matters.	  	 	18	 
		 	5.5	  	Indemnification; Successor Indemnification	  	 	18	 
		 	5.6	  	Indemnification Matters	  	 	19	 
		 	5.7	  	Qualified Small Business Stock	  	 	19	 
		 	5.8	  	Termination of Covenants	  	 	19	 
		 	5.9	  	FCPA	  	 	20	 
		 	5.10	  	Right to Conduct Activities	  	 	20	 
			
	6.	 	 Miscellaneous
	  	 	20	 


  
 i 














									
		 	6.1	  	 Successors and Assigns
	  	 	20	 
		 	6.2	  	 Governing Law
	  	 	21	 
		 	6.3	  	 Counterparts
	  	 	21	 
		 	6.4	  	 Titles and Subtitles
	  	 	21	 
		 	6.5	  	 Notices
	  	 	21	 
		 	6.6	  	 Amendments and Waivers
	  	 	22	 
		 	6.7	  	 Severability
	  	 	23	 
		 	6.8	  	 Aggregation of Stock
	  	 	23	 
		 	6.9	  	 Additional Investors
	  	 	23	 
		 	6.10	  	 Entire Agreement
	  	 	23	 
		 	6.11	  	 Dispute Resolution
	  	 	23	 
		 	6.12	  	 Delays or Omissions
	  	 	24	 
			
	 Schedule A
	  	-     Schedule of Investors	  			
	 Schedule B
	  	-     Schedule of Founders	  			


  
 ii 













 AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the [8th] day of May, 2019, by and
among ViraCyte, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on
Schedule B hereto, each of whom is referred to herein as a “Founder” that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred Stock
and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to that certain Investors’ Rights Agreement dated as of September 17, 2018,
as amended on December 18, 2018, by and among the Company and such Existing Investors (the “Prior Agreement”); 

WHEREAS, the Existing Investors are holders of at least a majority of the Registrable Securities of the Company (as defined in the
Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and 

WHEREAS, certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even date herewith by and
among the Company and such Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such Investors, Existing
Investors holding at least a majority of the Registrable Securities, and the Company. 
 NOW, THEREFORE, the Existing Investors
hereby agree that the Prior Agreement shall be amended and restated, and the parties to this Agreement further agree as follows: 

1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund, other investment fund or registered
investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or registered investment adviser with, such Person. 

1.2    “Board of Directors” means the board of directors of the Company. 

1.3    “Certificate of Incorporation” means the Company’s Second Amended and Restated Certificate of
Incorporation, as amended and/or restated from time to time. 
 1.4    “Common Stock” means shares of the
Company’s common stock, par value $0.0001 per share. 
 1.5    “Competitor” means a Person engaged,
directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now 












 
existing or formed hereafter)), in a business that offers products or services that are directly or indirectly competitive with the products or services of the Company, including products or
services which are in actual or demonstrably anticipated research or development by the Company, but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent
(20)% of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor; provided, that ElevateBio, LLC (“ElevateBio”), Gilead
Sciences, Inc. (“Gilead”), Redmile Biopharma Investments II, L.P. (“Redmile”) and Artal International S.C.A. and its Affiliates (“Invus”) shall not be deemed a Competitor for purposes of this Agreement. 

1.6    “Crossover Financing” means the issuance and sale of the shares of Series B Preferred Stock pursuant to
the Purchase Agreement. 
 1.7    “Damages” means any loss, damage, claim or liability (joint or several) to
which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any
untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents
or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.8    “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable
for (in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.9    “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.10    “Excluded Registration” means (i) a registration relating to the sale or grant of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered. 
 1.11    “FOIA Party” means a Person
that, in the reasonable determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of
Information Act, 5 U.S.C. 552 (“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.12    “Form S-1” means such form under the Securities Act as in
effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.13    “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

  
 2 













 1.14    “GAAP” means generally accepted accounting principles
in the United States as in effect from time to time. 
 1.15    “Holder” means any holder of Registrable
Securities who is a party to this Agreement. 
 1.16    “Immediate Family Member” means a child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.17    “Initiating Holders” means, collectively, Holders who properly initiate a registration request under
this Agreement. 
 1.18    “IPO” means the Company’s first public offering of its Common Stock under the
Securities Act. 
 1.19    “Key Employee” means each Founder, any executive-level employee or consultant
(including, division director and vice president-level positions) as well as any employee or consultant who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the
Purchase Agreement). 
 1.20    “Major Investor” means any Investor that, individually or together with such
Investor’s Affiliates, holds at least (a) 20,000,000 shares of Common Stock issuable or issued upon conversion of the Series A Preferred Stock and/or (b) 1,000,0000 shares of Common Stock issuable or issued upon conversion of the Series B
Preferred Stock, both as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof, held by such Investor on the date hereof. 

1.21    “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities, excluding any
securities offered or sold pursuant to the terms of the Purchase Agreement. 
 1.22    “Person” means any
individual, corporation, partnership, trust, limited liability company, association or other entity. 

1.23    “Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock and Series
B Preferred Stock. 
 1.24    “Registrable Securities” means (i) the Common Stock issuable or issued
upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date
hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the
shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection
6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

  
 3 













 1.25    “Registrable Securities then outstanding” means the
number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible
securities that are Registrable Securities. 
 1.26    “Restricted Securities” means the securities of the
Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 

1.27    “SEC” means the Securities and Exchange Commission. 

1.28    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.29    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.30    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 1.31    “Selling Expenses” means all underwriting discounts, selling commissions,
and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in
Subsection 2.6. 
 1.32    “Series A Director” means any director of the Company that the holders of
record of the Series A Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 

1.33    “Series A Preferred Stock” means collectively, shares of the Company’s Series A2 Preferred Stock,
Series A3 Preferred Stock and Series A4 Preferred Stock. 
 1.34    “Series A2 Preferred Stock” means shares
of the Company’s Series A2 Preferred Stock, par value $0.0001 per share. 
 1.35    “Series A3 Preferred
Stock” means shares of the Company’s Series A3 Preferred Stock, par value $0.0001 per share. 

1.36    “Series A4 Preferred Stock” means shares of the Company’s Series A4 Preferred Stock, par value
$0.0001 per share. 
 1.37    “Series B Preferred Stock” means shares of the Company’s Series B
Preferred Stock, par value $0.0001 per share. 
 2.    Registration Rights. The Company covenants and agrees as
follows: 
 2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the earlier of (i) five (5)
years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration 

  
 4 













 
statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form
S-1 registration statement, for an aggregate offering price of at least $50 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof
(the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in
such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections
2.1(c) and 2.3. 
 (b)    Form S-3 Demand. If at any
time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least a majority of the Registrable Securities then outstanding that the Company file a Form
S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $25 million, then the
Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant
to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such
registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition,
corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall
be tolled correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period.

 (d)    The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Subsection 2.1(a): (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of,
a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations
pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made
pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b): (i) during the period that is sixty (60) days before the Company’s
good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable
efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the
date of such request. A 

  
 5 













 
registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective
by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which
case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection
2.1(c), then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2    Company Registration. If the Company proposes to register (including, for this purpose, a registration
effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at
such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3,
cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection
2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the
Company in accordance with Subsection 2.6. 
 2.3    Underwriting Requirements. 

(a)    If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be
selected by the Board of Directors and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting; provided, however, that no Holder (or any of
their assignees) shall be required to make any representations, warranties or indemnities except as they relate to such Holder’s ownership of shares and authority to enter into the underwriting agreement and to such Holder’s intended
method of distribution, and the liability of such Holder shall be limited to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other provision of this Subsection 2.3, if the managing
underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would
be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be
included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may
round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 
 (b)    In
connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of 

  
 6 













 
the Holders’ Registrable Securities in such underwriting unless the Holders seeking to sell Registrable Securities in such offering accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the
number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities
included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the
determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired
members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of
Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c)    For purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result
of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are
actually included. 
 2.4    Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a
period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration
of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to one hundred eighty (180) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

  
 7 













 (b)    prepare and file with the SEC such amendments and supplements to
such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

 (c)    furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as
required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business
or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e)    in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f)    use its commercially
reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities
issued by the Company are then listed; 
 (g)    provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of
the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or
advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after
any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under
Rule 10b5-1 of the Exchange Act. 

  
 8 













 2.5    Furnish Information. It shall be a condition precedent to
the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself,
the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6    Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to this Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and
the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered
(in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to
forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse
change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be
required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8    Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a)    To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each
Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person
any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in
this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b)    To the extent
permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company
within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling


  
 9 













 
Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon
and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal
or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further
that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under this Subsection 2.8(b) and Subsection 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling
Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 
 (c)    Promptly
after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a
claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to
the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an
indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d)    To provide for just and equitable contribution to joint liability under the Securities Act in any case in which
either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such
case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the
aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party
in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder
will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s
liability pursuant to this 

  
 10 













 
Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by
such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f)    Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public
offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall
survive the termination of this Agreement. 
 2.9    Reports Under Exchange Act. With a view to making available
to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 
 (a)    make and keep available adequate current public
information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b)    use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting
requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company
shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) provide to
such holder or prospective holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in
the registration and offering all shares of Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder;
provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11    “Market Stand-off”
Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the 

  
 11 













 
effective date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act, and ending on the date
specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory
restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any
successor provisions or amendments thereto), (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the
registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction
described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall (A) apply only to the IPO, (B) shall
not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, (C) not apply to any shares purchased in the IPO or in the open market after the IPO, (D) not apply to the transfer of any shares to any trust for
the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not
involve a disposition for value, and (E) be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company obtains a similar agreement from all stockholders individually owning more than one
percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended
third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute
such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. If any of the obligations described in
this Subsection 2.11 are waived or terminated with respect to any of the securities of any such Holder, officer, director or greater than one-percent stockholder (in any such case, the
“Released Securities”), the foregoing provisions shall be waived or terminated, as applicable, to the same extent and with respect to the same percentage of securities of each Holder as the percentage of Released Securities represent with
respect to the securities held by the applicable Holder, officer, director or greater than one-percent stockholder. 

2.12    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. 
 (b)    Each certificate, instrument,
or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend,
recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

  
 12 













 THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF
WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and giving
instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects
with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof
shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such
Holder distributes Restricted Securities to an Affiliate of such Holder; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the
Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such
certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities
Act. 
 2.13    Termination of Registration Rights. The right of any Holder to request registration or inclusion
of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a)    the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 

(b)    such time after consummation of the IPO as Rule 144 or another similar exemption under the Securities Act is
available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c)    the fifth anniversary of the IPO. 

  
 13 













 3.    Information and Observer Rights. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that
the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company: 

(a)    as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited
income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may
(i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(b)    as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three
(3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such
financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c)    as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal
year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial
statements audited and certified by independent public accountants of regionally recognized standing selected by the Company; 

(d)    as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three
(3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period,
the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock
options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief
executive officer of the Company as being true, complete, and correct; 
 (e)    as soon as practicable, but in any
event thirty (30) days before the end of each fiscal year, a comprehensive budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including
balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; 

(f)    with respect to the financial statements called for in Subsection 3.1(a), Subsection 3.1(b) and
Subsection 3.1(c), an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently applied with prior practice for
earlier periods (except as otherwise set forth in Subsection 3.1(a), Subsection 3.1(b) and Subsection 3.1(c)) and fairly present the financial condition of the Company and its results of operation for the periods specified
therein; and 
 (g)    such other information relating to the financial condition, business, prospects, or corporate
affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide 

  
 14 













 
information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form
acceptable to the Company), or in the case of this Section 3.1(g) competitive information; or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in
this Subsection 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC
rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. 
 3.2    Inspection. The Company
shall permit each Major Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s
properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be competitive information, trade secret or
confidential information or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3    Observer Rights. As long as Gilead (and its Affiliates, collectively) owns not less than fifty percent
(50%) of the shares of the Series B Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Gilead to attend all regularly
scheduled meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided,
however, that at the Company’s request, the Company and such representative shall enter into a confidentiality agreement in customary form reasonably acceptable to Gilead; and provided further, that the Company reserves the
right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its
counsel or result in disclosure of trade secrets or a conflict of interest. As long as Redmile owns not less than fifty percent (50%) of the shares of the Series B Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent
amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of Redmile to attend all regularly scheduled meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such
representative copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner
with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or
attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of competitive information, trade secrets or a conflict of interest. 

  
 15 













 3.4    Termination of Information and Observer Rights.
The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation in which the
consideration received by Investors consists only of cash and/or marketable securities, whichever event occurs first. 

3.5    Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose,
divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a
registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been
independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to
obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this
Subsection 3.5 and is not a Competitor; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor
informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that
such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4.    Rights to Future Stock Issuances. 

4.1    Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable
securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor and each Founder. The Founders, as a group, and a Major Investor shall be entitled to apportion
the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having
“beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Founder and such Major Investor (“Investor Beneficial Owners”); provided
that each such Affiliate or Investor Beneficial Owner (x) is not a Competitor or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, (y) agrees to enter into this
Agreement and each of the Amended and Restated Voting Agreement and Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other
parties named therein, as an “Investor” under each such agreement (provided that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor under Subsections 3.1, 3.2 and this
Subsection 4.1 hereof), and (z) agrees to purchase at least such number of New Securities as are allocable hereunder to the Major Investor holding the fewest number of Preferred Stock and any other Derivative
Securities. 
 (a)    The Company shall give notice (the “Offer Notice”) to each Major Investor, stating
(i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

  
 16 













 (b)    By notification to the Company within twenty (20) days
after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock
then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major
Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such twenty
(20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise.
During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to
that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or
indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection
4.1(b) shall occur within the later of one hundred and twenty (120) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

(c)    If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or
Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement
is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this
Subsection 4.1. 
 (d)    The right of first offer in this Subsection 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Certificate of Incorporation); and (ii) shares of Common Stock issued in the IPO. 

(e)    Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this
Subsection 4.1, the Company may elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each Major Investor
shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s percentage-ownership position, calculated as
set forth in Subsection 4.1(b) before giving effect to the issuance of such New Securities. 

4.2    Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or
effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed
Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

  
 17 













 5.    Additional Covenants. 

5.1    Insurance. The Company shall maintain Directors and Officers liability insurance, each in an amount and on
terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should be
discontinued. Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as a Preferred Director (as defined in the Certificate of Incorporation) is serving on the Board of Directors, the Company
shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least $3 million dollars unless approved by such Preferred Directors, and the Company shall annually, within one hundred twenty (120) days
after the end of each fiscal year of the Company, deliver to the Investors a certification that such a Directors and Officers liability insurance policy remains in effect. 

5.2    Employee Agreements. The Company will cause (i) each Person now or hereafter employed by it or by any
subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and
(ii) each Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or
otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Series A2 Directors. 

5.3    Employee Stock. Unless otherwise approved by the Board of Directors, all future employees and
consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing
for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal
quarterly installments over the following twelve (12) quarters, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. Without the prior approval by the Board of
Directors, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be
inconsistent with this Subsection 5.3. In addition, unless otherwise approved by the Board of Directors, the Company shall retain (and not waive) a “right of first refusal” on employee transfers until the Company’s IPO
and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4    Board Matters. 

(a)    The Board of Directors shall convene for meetings at least quarterly, unless otherwise approved by the Board of
Directors. 
 (b)    Upon request, the Company shall promptly reimburse in full, each
non-employee director of the Company for his or her reasonable, customary and documented out-of-pocket expenses incurred in the
course of business conducted on behalf of the Company (including without limitation attendance of meetings of the Board of Directors).

5.5    Indemnification; Successor Indemnification. The Company shall use its best efforts to provide that its
Certificate and Bylaws provide for indemnification of officers and directors of the Company to the maximum extent permitted by law. The Company shall enter into a customary indemnification agreement in a form satisfactory to the Investors with each
member of the Board of Directors. If the Company or any of its successors or assignees consolidates with or merges into any other 

  
 18 













 
Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and
assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be. 
 5.6    Indemnification Matters.
The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses
and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its
obligations to any such Investor Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary),
(b) that it shall be required to advance the full amount of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any
such Investor Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such
Investor Director may have against the Investor Indemnitors, and (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any
other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought
indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director
against the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this Subsection 5.6 and shall have the right, power and authority to enforce the
provisions of this Subsection 5.6 as though they were a party to this Agreement. 
 5.7    Qualified Small
Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Series A Preferred Stock, as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue
Code (the “Code”), to constitute “qualified small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors of the Company
determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company; provided further, that in no event shall the Company be liable to the Investors or any other party for any damages
arising from the shares failing to qualify as “qualified small business stock” as defined in Section 1202(c) of the Code. The Company shall upon request use commercially reasonable efforts to submit to its stockholders (including the
Investors) and to the Internal Revenue Service any reports that are required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, after any Investor’s written request therefor, the Company
shall use commercially reasonable efforts to deliver to such Investor such factual information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s
interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. 

5.8    Termination of Covenants. The covenants set forth in this Section 5, except for
Subsections 5.5, and 5.6, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

  
 19 













 5.9    FCPA. The Company represents that it shall not (and shall
not permit any of its subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute
any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)),
in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or
their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation
of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls
(including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to
provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase
Agreement). The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or
indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 

5.10    Right to Conduct Activities. The Company hereby agrees and acknowledges that Gilead (together with its
Affiliates) and Redmile (together with its Affiliates) are engaged in investment activities, and as such review the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the
Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, Gilead (and its Affiliates) and Redmile (and its Affiliates) shall not be
liable to the Company for any claim arising out of, or based upon, (i) the investment by Gilead (or its Affiliates) or Redmile (or its Affiliates) in any entity competitive with the Company, or (ii) actions taken by any partner, officer,
employee or other representative of Gilead (or its Affiliates) or Redmile (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or
otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure and/or use of the
Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

6.    Miscellaneous. 

6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with all related
obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate, partner or stockholder of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or
more of such Holder’s Immediate Family Members; (iii) after such transfer, holds at least 500,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other
recapitalizations); or (iv) is a transferee of all Registrable Securities held by such Holder immediately prior to such transfer; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with
written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and
subject to 

  
 20 













 
the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the
holdings of a transferee (1) that is an Affiliate, partner or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate
Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon
the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights,
remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2    Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without
regard to any conflict of laws rules that would require the application of the laws of any other jurisdiction. 

6.3    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4    Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not
to be considered in construing or interpreting this Agreement. 
 6.5    Notices. 

(a)    All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent
during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the
business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective
parties at their addresses as set forth on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email
address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to (which copy shall not constitute
notice): Goodwin Procter LLP, Attn: Mitchell Bloom and Danielle Lauzon, 100 Northern Ave., Boston, MA 02210, and if notice is given to the Investors, a copy shall also be sent to (which copy shall not constitute notice): Greenberg Traurig, LLP, One
International Place, Suite 2000, Boston, MA 02110 Attention: Abdullah Malik and Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404 Attention: Thomas Kennedy. 

(b)    Consent to Electronic Notice. Each Investor and Founder consents to the delivery of any stockholder notice
pursuant to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the
facsimile number set forth below such 

  
 21 













 
Investor’s or Founder’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by
means of electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted Electronic Notice shall
be ineffective and deemed to not have been given. Each Investor and Founder agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing.
Notwithstanding anything to the contrary in the provisions of Subsection 6.5(a) and this Subsection 6.5(b), Gilead expressly withholds consent to notice by electronic mail under this Agreement and neither the Company nor any other
party hereto may provide notice or other communications hereunder to Gilead via electronic mail. 

6.6    Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the
observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least a majority of the Registrable
Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment
allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to
all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction), (b) Subsections 3.1 and
3.2, Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Subsection 6.6 and Section 4 and any other section of
this Agreement applicable to the Founders including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written consent of the holders of at least a majority of the Registrable
Securities then outstanding and held by the Founders or the Major Investors, as applicable, and (c) Subsections 1.5, 3.3, and 5.10 may not be amended, modified, terminated or waived without the written consent of Gilead, to
the extent that such amendment or modification involves Gilead. Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of
this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor
who becomes a party to this Agreement in accordance with Subsection 6.9. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent
in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such
party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or
provision. Notwithstanding the foregoing, in the event that (A) (1) Section 4 of this Agreement is waived pursuant to the consent required by this Section 6.6 or (2) the definition of “Additional Shares of Common Stock”
under the Restated Certificate is amended, waived or excluded, in each case, with respect to a transaction and (B) any Major Investor subsequently participates in such transaction by agreement with the Company (each such Investor, a
“Participating Investor”), then the Company shall provide to each other Major Investor whose rights were waived or amended a right to purchase the same proportion (up to 100%) of such Major Investor’s pro rata share of the New
Securities being offered by the Company in the relevant transaction as is being purchased by the Participating Investor purchasing the largest portion of such Participating Investor’s pro rata share, subject to the notice and election periods
set forth in Section 4. 

  
 22 













 6.7    Severability. In case any one or more of the provisions
contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or
unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8    Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9    Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues
additional shares of the Company’s Series B Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Series B Preferred Stock may become a party to this Agreement by
executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this
Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10    Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and
entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness
of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.11    Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction
of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware or the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to
commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to
assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or
execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT,
THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND
THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY
EACH OF THE PARTIES HERETO AND 

  
 23 













 
THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH
PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 The prevailing party shall be
entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action
sought in the U.S. District Court for the District of Delaware or any court of the State of Delaware having subject matter jurisdiction. 

6.12    Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party
under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any
such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under
this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 [Remainder of Page Intentionally
Left Blank] 

  
 24 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	VIRACYTE, INC.
		
	By:	 	 /s/ Vikas Sinha

	Name:	 	Vikas Sinha
	Title:	 	President
	
	Address:


  
 [Signature Page to ViraCyte, Inc.
– Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	FOUNDERS/INVESTORS:


 
			
		
		 	 /s/ John Wilson

		 	Signature
		
	Name:	 	John Wilson
		
		 	 /s/ John Wilson

		 	Signature
		
	Name:	 	John Wilson


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	FOUNDERS/INVESTORS:


 
			
		
		 	 /s/ Helen Heslop

		 	Signature
		
	Name:	 	Helen Heslop
		
		 	 /s/ Helen Heslop

		 	Signature
		
	Name:	 	Helen Heslop


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	FOUNDERS/INVESTORS:


 
			
		
		 	 /s/ Juan Vera

		 	Signature
		
	Name:	 	Juan Vera
		
		 	 /s/ Juan Vera

		 	Signature
		
	Name:	 	Juan Vera


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	FOUNDERS/INVESTORS:


 
			
	
	        Salt Free LP
		
		 	 /s/ Malcolm K. Brenner

		 	Signature
		
	Name:	 	malcolm k brenner
	
	        Salt Free LP
		
		 	 /s/ Malcolm K. Brenner

		 	Signature
		
	Name:	 	malcolm k brenner


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	FOUNDERS/INVESTORS:


 
			
		
		 	 /s/ Ann Leen

		 	Signature
		
	Name:	 	Ann Leen
		
		 	 /s/ Ann Leen

		 	Signature
		
	Name:	 	Ann Leen


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Fidelity Contrafund: Fidelity Contrafund
		
	By:	 	 /s/ Colm Hogan

	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory
	
	Fidelity Contrafund Commingled Pool
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	 /s/ Colm Hogan

	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory
	
	Fidelity Contrafund: Fidelity Contrafund K6
		
	By:	 	 /s/ Colm Hogan

	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory
	
	Fidelity Mt. Vernon Street Trust: Fidelity Series
	Growth Company Fund
		
	By:	 	 /s/ Colm Hogan

	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory
	
	Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund
		
	By:	 	 /s/ Colm Hogan

	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory
	
	Fidelity Growth Company Commingled Pool
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	 /s/ Colm Hogan

	Name:	 	Colm Hogan
	Title:	 	Authorized Signatory


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Gilead Sciences, Inc.
		
	By:	 	 /s/ Daniel O’Day

	Name:	 	Daniel O’Day
	Title:	 	Chairman & CEO


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Redmile Biopharma Investments II, L.P.
		
	By:	 	 /s/ Jeremy Green

	Name:	 	Jeremy Green
	Title:	 	Managing Member of the General Partner and the Management Company


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Artal International S.C.A.
	By Artal International Management SA, its
	Managing Partner
		
	By:	 	 /s/ Anne Goffard

	Name:	 	Anne Goffard
	Title:	 	Managing Director


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	F2 TPO INVESTMENT, LLC
	acting by its Manager Globeways Holdings II Limited
		
	By:	 	 /s/ ILLEGIBLE

	Name:	 	
	Title:	 	


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	F2 MG LIMITED
		
	By:	 	 /s/ Rachel Higham

	Name:	 	Rachel Higham
	Title: 	 	Director, Cellar Limited
		
	By:	 	 /s/ ILLEGIBLE

	Name:	 	ILLEGIBLE
	Title: 	 	Director, Clambake Limited


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	F2 MC, LLC
	acting by its Manager Globeways Holdings II Limited
		
	By:	 	 /s/ ILLEGIBLE

	Name:
	Title:


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Sara International Limited
		
	By:	 	 /s/ Umesh Saraf

	Name:	 	Umesh Saraf
	Title:	 	Director
		
	Address:	 	 13/F. Chun Wo Commercial Centre
 23-29, Wing
Wo Street Central
 Hong Kong



 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SAMSARA BIOCAPITAL, L.P.
		
	By:	 	Samsara BioCapital GP, LLC, General Partner
		
	By:	 	 /s/ Srinivas Akkaraju

	Name:	 	Srinivas Akkaraju, MD, PhD
	Title:	 	Managing Member


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	EcoR1 Capital Fund, L.P.
	By:	 	EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

	Name:	 	Oleg Nodelman,
	Title:	 	Managing Director
	
	EcoR1 Capital Fund Qualified, L.P.
	By:	 	EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

	Name:	 	Oleg Nodelman,
	Title:	 	Managing Director


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	LEERINK PARTNERS CO-INVESTMENT FUND, LLC
		
	By:	 	 /s/ Jeffrey A. Leerink

	Name: Jeffrey A. Leerink
	Title: Manager



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Andrew Arthur

		 	Signature
		
	Name:	 	Andrew Arthur



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Ali Behbahani

		 	Signature
		
	Name:	 	Ali Behbahani



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Jacqueline Christman

		 	Signature
		
	Name:	 	Jacqueline Christman



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Joe Dziedzic

		 	Signature
		
	Name:	 	Joe Dziedzic



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Peter Hoang

		 	Signature
		
	Name:	 	Peter Hoang


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ James Hannigan

		 	Signature
		
	Name:	 	James Hannigan


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Stephen Handley

		 	Signature
		
	Name:	 	Stephen Handley


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Madeline Giroir

		 	Signature
		
	Name:	 	Madeline Giroir


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Bambi Grilley

		 	Signature
		
	Name:	 	Bambi Grilley


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Brett H Larson

		 	Signature
		
	Name:	 	Brett H Larson


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Eliot Laurence

		 	Signature
		
	Name:	 	Eliot Laurence


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Daniel E. Lee

		 	Signature
		
	Name:	 	Daniel E. Lee


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Devan V. Padmanabhan

		 	Signature
		
	Name:	 	Devan V. Padmanabhan


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Kruti Patel

		 	Signature
		
	Name:	 	Kruti Patel


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Reed A. Smith

		 	Signature
		
	Name:	 	Reed A. Smith



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Ifigeneia Tzannou

		 	Signature
		
	Name:	 	Ifigeneia Tzannou



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
		 	 /s/ Daniel Welch

		 	Signature
		
	Name:	 	Daniel Welch



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTOR:
		
		 	 /s/ Scott Phillips

		 	(Signature)
		
	Name:	 	Scott Phillips



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTOR:
		
		 	 /s/ Edward Miller

		 	(Signature)
		
	Name:	 	Edward Miller



  
 [Signature Page to
ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR: GUY BROADBENT 2003 TRUST


 
			
		
		 	 /s/ Guy Broadbent

		 	(Signature)
		
	Name:	 	GUY BROADBENT, TRUSTEE


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Shailesh J. Patel

		 	(Signature)
		
	Name:	 	Shailesh J. Patel


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Vivekauand Kamath

		 	(Signature)
		
	Name:	 	 Vivekauand Kamath



 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ James E. Maoigan

		 	(Signature)
		
	Name:	 	JAMES E. MAOIGAN


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:	 	


 
			
		
		 	 /s/ Sanjeev Acharya

		 	(Signature)
		
	Name:	 	Sanjeev Acharya


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Shrikant Nadkarni

		 	(Signature)
		
	Name:	 	Shrikant Nadkarni


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Arnold Wright

		 	(Signature)
		
	Name:	 	Arnold Wright


 [Signature Page to ViraCyte. Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	Whipstick Ventures, LLC
		
	 By:
	 	 /s/ Jeffrey S. Bornstein

	Name:	 	Jeffrey S. Bornstein
	Title:	 	Principal


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Sudipta Dey

		 	(Signature)
		
	Name:	 	Sudipta Dey 


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement]













 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Van W.L. Dusenbury

		 	(Signature)
		
	Name:	 	Van W.L. Dusenbury


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Henry Dusenbury

		 	(Signature)
		
	Name:	 	Henry Dusenbury


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Josh Sorafine

		 	(Signature)
		
	Name:	 	Josh Sorafine


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Brett Hagen

		 	(Signature)
		
	Name:	 	Brett Hagen


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Robert Erman

		 	(Signature)
		
	Name:	 	Robert Erman


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Michael J Balyma

		 	(Signature)
		
	Name:	 	Michael J Balyma


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Dinesh S. Pashankar

		 	(Signature)
		
	Name:	 	Dinesh S. Pashankar


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Bhakti Bhargava

		 	(Signature)
		
	Name:	 	Bhakti Bhargava


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Anirban Chatterjee

		 	(Signature)
		
	Name:	 	Anirban Chatterjee


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Dhanpat Jain

		 	(Signature)
		
	Name:	 	Dhanpat Jain


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Jeroen van Beek

		 	(Signature)
		
	Name:	 	Jeroen van Beek


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Sonia Deggs

		 	(Signature)
		
	Name:	 	Sonia Deggs


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Sarfraz Nawaz

		 	(Signature)
		
	Name:	 	Sarfraz Nawaz


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Frederick Daley

		 	(Signature)
		
	Name:	 	Frederick Daley


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Michael Paglia

		 	(Signature)
		
	Name:	 	Michael Paglia


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Jeffrey Cram

		 	(Signature)
		
	Name:	 	Jeffrey Cram


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Majd Mouded

		 	(Signature)
		
	Name:	 	Majd Mouded


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Jed Wiltzius

		 	(Signature)
		
	Name:	 	Jed Wiltzius


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
		
		 	 /s/ Arthur Maxwell

		 	(Signature)
		
	Name:	 	Arthur Maxwell


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ELEVATEBIO, LLC


 
			
		
	By:	 	     /s/ David
Hallal



 
			
	Name:	 	David Hallal
	Title:	 	Chief Executive Officer


 [Signature Page to ViraCyte, Inc. – Series B A&R Investors’ Rights Agreement] 












 SCHEDULE A 

INVESTORS 
  

	
	 Name and Address

	
	 Fidelity Contrafund: Fidelity Contrafund
  

Mag & Co.
 c/o
Brown Brothers Harriman & Co.
 Attn: Corporate Actions /Vault

140 Broadway
 New York, NY
10005
 [***]

	
	 Fidelity Contrafund Commingled Pool
  

Mag & Co.
 c/o
Brown Brothers Harriman & Co.
 Attn: Corporate Actions /Vault

140 Broadway
 New York, NY
10005
 [***]

	
	 Fidelity Contrafund: Fidelity Contafund K6
  

The Northern Trust Company

Attn: Fidelity Client Team – GFS Custody, C-1N

801 South Canal Street

Chicago, IL 60607

Fidelity Contrafund: Fidelity Contrafund K6

Reference Account # F71083

[***]
 Fax number: 312-557-5417

	
	 Fidelity Mt. Vernon Street Trust: Fidelity Series Growth

Company Fund
  

Mag & Co.
 c/o
Brown Brothers Harriman & Co.
 Attn: Corporate Actions /Vault

140 Broadway
 New York, NY
10005
 [***]















	
	 Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund

 
 BNY MELLON

ONE BNY MELLON CENTER
 500
GRANT STREET AIM 151-2700
 PITTSBURGH, PA 15258

	
	 Fidelity Growth Company Commingled Pool

By: Fidelity Management Trust Company, as Trustee
  

Mag & Co.
 c/o
Brown Brothers Harriman & Co.
 Attn: Corporate Actions /Vault

140 Broadway
 New York, NY
10005
 [***]

	
	 Gilead Sciences Inc.
  

Attn: EVP, Corporate Development

Gilead Sciences, Inc.
 333
Lakeside Drive
 Foster City, CA 94404
  

with copy to:
  

Attn: General Counsel

Gilead Sciences, Inc.
 333
Lakeside Drive
 Foster City, CA 94404

	
	 Redmile Biopharma Investments II, L.P.
  

One Letterman Drive, Suite D3-300

The Presidio, San Francisco, CA 94129

	
	 Artal International S.C.A
  

44 Rue de la Vallee
 L-2661 Luxembourg

	
	 F2 TPO Investment, LLC
  

c/o LJ Skye
 Rue du Seyon
2
 CP 2048
 20001
Neuchatel, Switzerland

	
	 F2 MG Limited
  

c/o LJ Skye
 Rue du Seyon
2
 CP 2048
 20001
Neuchatel, Switzerland















	
	 F2 MC, LLC
  

c/o LJ Skye
 Rue du Seyon
2
 CP 2048
 20001
Neuchatel, Switzerland

	
	 Samsara Biocapital, L.P.
  

628 Middlefield Road
 Palo
Alto, CA 94301

	
	 Sara International
  

13/F. Chun Wo Commercial Centre

23-29 Wing Wo Street

Central, Hong Kong

	
	 EcoR1 Capital Fund, LP.
  

409 Illinois Street
 San
Francisco, CA 94158

	
	 EcoR1 Capital Fund Qualified, L.P.
  

409 Illinois Street
 San
Francisco, CA 94158

	
	 Arthur Maxwell

	
	 Dhanpat Jain

	
	 Sudipta DEY

	
	 Dinesh Pashankar

	
	 Brett Hagen

	
	 Scott Phillips

	
	 Sanjeev Acharya

	
	 Shailesh Patel

	
	 Vivekanand Kamath

	
	 Josh Sorafine

	
	 Jed Wiltzius















	
	
	 Anirban Chatterjee

	
	 Edward Miller

	
	 Van Dusenbury

	
	 Henry Dusenbury

	
	 Arnold Wright

	
	 Mike Paglia

	
	 Bhakti Bhargava

	
	 Shrikant Nadkarni

	
	 Jeff Cram

	
	 Majd Mouded

	
	 Mike Bahma

	
	 Frederick Daley

	
	 Sonia Deggs

	
	 Guy Broadbent

	
	 Sarfraz Nawaz

	
	 Jeroen Van Beek

	
	 Leerink

	
	 Whipstick Ventures

	
	 Rob Erman

	
	 Jim Madigan

	
	 ElevateBio, LLC

450 Kendall Street

Cambridge, MA 02142

	
	 Ann Leen

[***]















	
	
	 Juan Vera

[***]

	
	 Helen Heslop

[***]

	
	 Stephen Dziedzic

[***]

	
	 Joseph Dziedzic

[***]

	
	 Eliot Laurence

[***]

	
	 Andrew Arthur

[***]

	
	 Stephen Handley

[***]

	
	 James Hannigan

[***]

	
	 Reed Smith

[***]

	
	 Devan Padmanabhan

[***]

	
	 Daniel Welch

[***]















	
	
	 Brett Larson

[***]

	
	 Daniel Lee

[***]

	
	 John Wilson

[***]

	
	 Jacqueline Christman

[***]

	
	 Madeline Giroir

[***]

	
	 Salt Free Limited Partnership

[***]

	
	 Sunitha Kakarla

[***]

	
	 Kruti Patel

[***]

	
	 Ifigeneia Tzannou

[***]

	
	 Bambi Grilley

[***]

	
	 Ali Behbahani

[***]















	
	 Peter Hoang

[***]

	
	 Ulrike Gerdemann

[***]














 SCHEDULE B 

FOUNDERS 
  

	
	 Name and address

	
	 John Wilson

[***]

	
	 Juan Vera

[***]

	
	 Ann Leen

[***]

	
	 Helen Heslop

[***]

	
	 Salt Free Limited Partnership

[***]